BIOSENIC SA |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.0156 EUR | -4.29% |
|
-20.41% | -74.51% |
Valuation
| Fiscal Period: December | 2022 | 2023 | 2024 |
|---|---|---|---|
| Capitalization 1 | 9.485 | 2.863 | 2.863 |
| Enterprise Value (EV) 1 | 9.485 | 21.66 | 32.16 |
| P/E ratio | -3.06 x | -0.31 x | -0.17 x |
| Yield | - | - | - |
| Capitalization / Revenue | - | - | - |
| EV / Revenue | - | - | - |
| EV / EBITDA | - | -4.33 x | -2.85 x |
| EV / FCF | - | -4.25 x | -3.12 x |
| FCF Yield | - | -23.5% | -32% |
| Price to Book | - | -0.52 x | -0.16 x |
| Nbr of stocks (in thousands) | 154,978 | 183,526 | 183,526 |
| Reference price 2 | 0.0612 | 0.0156 | 0.0156 |
| Announcement Date | 4/24/23 | - | - |
1EUR in Million2EUR
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2022 | 2023 | 2024 |
|---|---|---|---|
| Net sales 1 | - | - | - |
| EBITDA 1 | - | -5 | -11.3 |
| EBIT 1 | -2.318 | -5.2 | -11.5 |
| Operating Margin | - | - | - |
| Earnings before Tax (EBT) | -3.049 | - | - |
| Net income 1 | -2.041 | -5.8 | -11.2 |
| Net margin | - | - | - |
| EPS 2 | -0.0200 | -0.0500 | -0.0900 |
| Free Cash Flow 1 | - | -5.1 | -10.3 |
| FCF margin | - | - | - |
| FCF Conversion (EBITDA) | - | - | - |
| FCF Conversion (Net income) | - | - | - |
| Dividend per Share | - | - | - |
| Announcement Date | 4/24/23 | - | - |
1EUR in Million2EUR
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2022 | 2023 | 2024 |
|---|---|---|---|
| Net Debt 1 | - | 18.8 | 29.3 |
| Net Cash position 1 | - | - | - |
| Leverage (Debt/EBITDA) | - | -3.76 x | -2.593 x |
| Free Cash Flow 1 | - | -5.1 | -10.3 |
| ROE (net income / shareholders' equity) | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - |
| Assets 1 | - | - | - |
| Book Value Per Share 2 | - | -0.0300 | -0.1000 |
| Cash Flow per Share 2 | - | -0.0400 | -0.0900 |
| Capex 1 | - | 0.2 | 0.2 |
| Capex / Sales | - | - | - |
| Announcement Date | 4/24/23 | - | - |
1EUR in Million2EUR
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
SELL
Number of Analysts
1
Last Close Price
0.0156
EUR
Average target price
0.1
EUR
Spread / Average Target
+541.03%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -74.51% | 3.06M | |
| +25.83% | 661B | |
| +27.00% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +13.09% | 231B | |
| +5.46% | 200B | |
| -9.61% | 195B | |
| -6.26% | 145B |
- Stock Market
- Equities
- BIOS Stock
- Financials BioSenic SA
